Schering-Plough Posaconazole NDA User Fee Date Is March 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Potential spring launch of invasive fungal infection agent Noxafil could be Schering’s next new product after Vytorin; the Zetia/Zocor combination’s user fee date is July 24. Schering’s remaining NME in Phase III is another anti-infective.
You may also be interested in...
Schering-Plough Noxafil Review Prolonged By Last-Minute Label, Data Integrity Issues
FDA review documents for the antifungal illustrate an unusual case of the agency missing the user fee target for a priority review application.
Schering-Plough Noxafil Review Prolonged By Last-Minute Label, Data Integrity Issues
FDA review documents for the antifungal illustrate an unusual case of the agency missing the user fee target for a priority review application.
Bayer Products Give Schering Cross-Promotion Opportunities
The acquisition of Bayer's primary care products will allow Schering-Plough to cross-market its own drugs to former Bayer customers